Sort
261,768 grants matching “gene therapy”
A Phase III Trial to Validate HP 129Xe MRI as a Functional Pulmonary Biomarker in Pediatric Lung Disease
$999,713Kiarash Emami · Polarean, Inc. · R44 · FY2017 · HL
Neonatal and Young Pediatric Kidney Preservation through Nanowarming and Vitrification
$999,705Bradley P Weegman · Expanse Bio Llc · R44 · FY2024 · AI
Molecular and Cellular Phenotype of Aging and iPS Cells
$999,701Joseph C Wu · Stanford University · RC1 · FY2010 · AG
Preclinical development of novel small molecule malaria drugs that overcome drug
$999,700David H Peyton · Designmedix, Inc. · R42 · FY2015 · AI
Beginnings: Diversifying Talent in Advanced Biologics Manufacturing
$999,691Baley Reeves · Texas A&M Engineering Experiment Station · · FY2024 · TIP
Immune Regulation in Mycobacterial and Fungal Infections
$999,676Daniel Barber · National Institute Of Allergy And Infectious Diseases · ZIA · FY2016 · AI
Dissecting and Targeting Deregulated Mitochondrial Apoptosis in Human Cancer
$999,639Loren D Walensky · Dana-Farber Cancer Inst · R35 · FY2024 · CA
Therapeutic Antibodies for Biofilm Infections
$999,628Lawrence Michael Kauvar · Trellis Bioscience, Inc. · R44 · FY2016 · AI
Development of TP-317 in Ulcerative Colitis
$999,624John Parkinson · Thetis Pharmaceuticals, Llc · R44 · FY2024 · DK
Long-acting PTH for hypoparathyroidism
$999,615Laura M Hales · Extend Biosciences, Inc. · R44 · FY2024 · DK
Long-acting PTH for hypoparathyroidism
$999,615Laura M Hales · Extend Biosciences, Inc. · R44 · FY2025 · DK
Avanzando Caminos (Leading Pathways): The Hispanic/Latino Cancer Survivorship Cohort Study.â
$999,612Frank J Penedo · University Of Miami Coral Gables · UG3 · FY2021 · CA
Expression-Based Multi-Gene Signatures for CRC Recurrence and Chemoselection
$999,610Christopher Sears · Ambergen, Inc · R44 · FY2011 · CA
Expression-Based Multi-Gene Signatures for CRC Recurrence and Chemoselection
$999,610Christopher Sears · Ambergen, Inc · R44 · FY2012 · CA
Expression-Based Multi-Gene Signatures for CRC Recurrence and Chemoselection
$999,610Christopher Sears · Ambergen, Inc · R44 · FY2010 · CA
Adaptive Clinical Efficacy Evaluation of ONC201 in Recurrent High Grade Glioma
$999,600Joshua E. Allen · Oncoceutics, Inc. · R44 · FY2019 · CA
Development of an oxygen delivery biotherapeutic for the preservation of myocardial function during pediatric cardiopulmonary bypass
$999,580Jonathan A Winger · Omniox, Inc. · R44 · FY2023 · HD
A treatment drug for triple negative breast cancer
$999,562Zhi-Ren Liu · Proda Biotech, Llc · U44 · FY2022 · CA
A treatment drug for triple negative breast cancer
$999,562Zhi-Ren Liu · Proda Biotech, Llc · U44 · FY2023 · CA
Discovery and Preclinical Development of Drugs for Anthrax, Plague and Tularemia
$999,509Christie G. Brouillette · University Of Alabama At Birmingham · U01 · FY2010 · AI
Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer
$999,501Upendra Marathi · 7 Hills Pharma, Llc · R42 · FY2018 · CA
Novel extra cellular RNA-based combinatorial RNA inhibition therapy
$999,500Anil K Sood · University Of Tx Md Anderson Can Ctr · UH3 · FY2015 · TR
Development of a novel therapeutic for the treatment of diabetic nephropathy and renal fibrosis
$999,500Fabio Cohen Tucci · Epigen Biosciences, Inc. · R44 · FY2018 · DK
Phase 1/2a Clinical Study of Descartes-30 in Acute Respiratory Distress Syndrome
$999,491Charles Andrew Stewart · Cartesian Therapeutics, Inc. · R44 · FY2022 · HL
SIRT1 in Skeletal Muscle Development, Regeneration, and Atrophy
$999,437Vittorio Sartorelli · National Institute Of Arthritis And Musculoskeletal And Skin Diseases · ZIA · FY2017 · AR